Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:27 PM ET
SYRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.94B
- EPS (TTM)
- -$1.92
- Dividend yield
- None
- 52-week range
- 18.12 – 110.18
- Day range
- 78.73 – 86.22
- Volume / Avg
- 490.51K / 1.22M
- Beta
- —
- Shares outstanding
- 92.29M
- Next earnings
- Nov 3, 2026
52-week range
SYRE stock today
On Oct 9, SYRE is trading at $85.99, adding $6.09 (7.62%), versus the S&P 500's 0.51% gain. Shares are 22.0% below their 52-week high of $110.18, set on Aug 19, 2026 and 374.6% above the 52-week low of $18.12, in the middle of the past year's range. SYRE is up 143.9% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 351.9%.
Spyre Therapeutics has posted a net loss over the last twelve months (EPS of -$1.92), so its P/E ratio is not meaningful. Spyre Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Spyre Therapeutics
Company profileSpyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Cameron Turtle DPHIL, Ph.D.
- Headquarters
- Waltham, MA
- Employees
- 125
- IPO year
- 2016
- Website
- spyre.com
Financial highlights
Full financialsIn fiscal 2025, Spyre Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Spyre Therapeutics reported a net loss of $155.2 million, compared with a loss of $208.0 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.00K | $2.33M | $18.74M |
| Growth | — | -100.00% | -61.96% | -87.57% | — |
| Net income | $-155.20M | $-208.02M | $-338.79M | $-83.81M | $-65.80M |
| EPS (diluted) | — | — | $13.76 | $-24.86 | $-25.02 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$120.21+39.80%
- Strong buy 1
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.79
- Last reported (Q1 2026)
- May 5, 2026
- EPS actual vs est.
- $-0.74 vs —
SYRE news
All SYRE newsSpyre Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRAXPraxis Precision Medicines Inc. | 264.00 | +0.17% | $7.37B | vs SYRE |
| IONSIonis Pharmaceuticals Inc. | 45.24 | +4.48% | $7.52B | vs SYRE |
| ABVXAbivax SA ADR | 87.75 | -1.46% | $7.66B | vs SYRE |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.85 | +1.02% | $6.91B | vs SYRE |
| ALKSAlkermes plc | 40.77 | +1.63% | $6.84B | vs SYRE |
| RYTMRhythm Pharmaceuticals Inc. | 92.45 | +3.13% | $6.37B | vs SYRE |
| TGTXTG Therapeutics Inc. | 55.01 | +3.13% | $8.42B | vs SYRE |
| KNSAKiniksa Pharmaceuticals International plc Class A | 80.39 | +2.08% | $6.27B | vs SYRE |
Indexes, lists and sector
Spyre Therapeutics stock FAQ
What is Spyre Therapeutics's stock price today?
SYRE last traded at $85.99 as of Oct 9, 1:27 PM EDT, up 7.62% on the day. Prices are delayed at least 15 minutes.
Does Spyre Therapeutics pay a dividend?
No. Spyre Therapeutics does not currently pay a regular cash dividend.
When is Spyre Therapeutics's next earnings date?
Spyre Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.79.
Who is Spyre Therapeutics's CEO?
Dr. Cameron Turtle DPHIL, Ph.D. is the chief executive officer of Spyre Therapeutics Inc., which has about 125 employees.
Has SYRE ever split its stock?
Yes. The most recent SYRE stock split was a 1-for-25 split on Sep 8, 2023.
What is the SYRE 52-week high?
The 52-week high for SYRE is $110.18 and the 52-week low is $18.12. The stock is currently 22.0% below its high.